- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Good
|
- 10-Q Quarterly report
- 10.1 2005 Equity Incentive Plan
- 10.2 Offer Letter Between the Company and Richard Murray, PH.D
- 10.3 Offer Letter Between the Company and David Iwanicki
- 10.4 Offer Letter Between the Company and Peter Calcott
- 31.1 Certification of Peo Pursuant to Rule 13A-14(A) or Rule 15D-14(A)
- 31.2 Certification of Pfo Pursuant to Rule 13A-14(A) or Rule 15D-14(A)
- 32.1 Certification of CEO and CFO Pursuant to Section 1350 18 U.s.c. 1350
EXHIBIT 32.1
CERTIFICATION
Mark McDade, Chief Executive Officer, and Andrew L. Guggenhime, Senior Vice President and Chief Financial Officer, of PDL BioPharma, Inc. (the “Registrant”), each hereby certifies in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on his knowledge:
(1) the Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
A signed original of this written statement required by Section 906 will be provided to the Securities and Exchange Commission or its staff upon request.
Dated: May 10, 2007
/s/ Mark McDade |
Mark McDade |
Chief Executive Officer |
(Principal Executive Officer) |
/s/ Andrew L. Guggenhime |
Andrew L. Guggenhime |
Senior Vice President and Chief Financial Officer |
(Principal Financial and Accounting Officer) |